Status:

TERMINATED

Study of Ataluren (PTC124) in Hemophilia A and B

Lead Sponsor:

PTC Therapeutics

Collaborating Sponsors:

Genzyme, a Sanofi Company

Conditions:

Hemophilia A

Hemophilia B

Eligibility:

MALE

18+ years

Phase:

PHASE2

Brief Summary

Hemophilia A (HA) and hemophilia B (HB) are inherited bleeding disorders caused by mutations in the gene for factor VIII (FVIII) and factor IX (FIX), respectively. These proteins are essential for blo...

Detailed Description

In this study, participants with hemophilia A or hemophilia B due to a nonsense mutation were treated with an investigational drug called ataluren (PTC124). Evaluation procedures to determine if a par...

Eligibility Criteria

Inclusion

  • Ability to provide written informed consent
  • Age ≥18 years
  • Presence of a nonsense mutation as the sole disease-causing mutation in the FVIII or FIX gene
  • At least 20 prior treatments with FVIII or FIX concentrates
  • Willingness and ability to comply with scheduled visits, drug administration plan, study restrictions, and study procedures

Exclusion

  • Known hypersensitivity to any of the ingredients or excipients of the study drug
  • Any history of prior anti-FVIII/FIX inhibitors
  • Unable or unwilling to forego prophylactic FVIII/FIX concentrate use during the screening and on-study periods (Note: Participants were allowed use of FVIII/FIX concentrates for treatment of bleeding episodes while on study)

Key Trial Info

Start Date :

October 14 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 30 2011

Estimated Enrollment :

13 Patients enrolled

Trial Details

Trial ID

NCT00947193

Start Date

October 14 2009

End Date

August 30 2011

Last Update

June 16 2020

Active Locations (13)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (13 locations)

1

The Bleeding and Clotting Disorders Institute

Peoria, Illinois, United States, 61614

2

St. Vincent Indianapolis Hospital

Indianapolis, Indiana, United States, 46260

3

New England Hemophilia Center

Worcester, Massachusetts, United States, 01605

4

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States, 45229